Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease

Digestive Diseases and Sciences

Volumn 56, Issue 12, 2011, Pages 3439-3449

  Nseir, W ^a,c   Shalata, A ^b   Marmor, A ^b   Assy, N ^b,c  

^a Israel   (Israel)

^b Rebecca Sieff Government Hospital   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cardiovascular disease; Coronary artery diseases; Fatty liver; Mechanism; NAFLD; Steatohepatitis

Indexed keywords

ADIPONECTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; INSULIN; METFORMIN; PIOGLITAZONE;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FIBRINOLYSIS; FOOD INTAKE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPOTOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; DISEASE COURSE; FATTY LIVER; HEALTH; INCIDENCE; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FATTY LIVER; HUMANS; INCIDENCE; LIPID METABOLISM; OXIDATIVE STRESS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; WORLD HEALTH;

EID: 84856264322     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1767-y     Document Type: Review

References (142)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
2. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-240. (Pubitemid 46400718)
3. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;4:917-923. (Pubitemid 36397405)
4. Younossi Z, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35: 746-752. (Pubitemid 34258367)
5. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis. 2010;28:162-168.
6. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082-1089.
7. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systemic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;30:403-414. (Pubitemid 46135879)
8. Ford ES, Schulze MB, Pischon T, Bergmann MM, Joost HG, Boeing H. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc Diabetol. 2008;7:35.
9. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;9: 1898-1904.
10. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;21:2709-2716. (Pubitemid 35403784)
11. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689. (Pubitemid 32893993)
12. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;10:1245-1250. (Pubitemid 39202340)
13. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. (Pubitemid 39657013)
14. Sagi R, Reif S, Neuman G, Webb M, Phillip M, Shalitin S. Nonalcoholic fatty liver disease in overweight children and adolescents. Acta Paediatr. 2007;96:1209-1213. (Pubitemid 47106536)
15. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579-1584. (Pubitemid 46672668)
16. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009;51:918-924.
17. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care. 2004;10:2498-2500. (Pubitemid 39281410)
18. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;5:1040-1050.
19. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005;11: 4838-4842.
20. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;2:473-480. (Pubitemid 41061101)
21. Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;6:369-374. (Pubitemid 40826835)
22. Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet Med. 2006;23:403-409.
23. Targher G, Bertolini L, Padovani R, et al. Relation between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325-1330. (Pubitemid 44125930)
24. Akabame S, Hamaguchi M, Tomiyasu K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008;72:618-625. (Pubitemid 351679416)
25. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254:393-400.
26. Pacifico L, Cantisani V, Ricci P, et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Paediatr Res. 2008;63:423-427. (Pubitemid 351450591)
27. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;1:113-121. (Pubitemid 41002048)
28. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;6: 1413-1419. (Pubitemid 29258890)
29. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541-3546. (Pubitemid 43334347)
30. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;8:2119-2121. (Pubitemid 47219432)
31. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;9:2263-2271.
32. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005;14:2130-2137. (Pubitemid 41475806)
33. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;1:127-133. (Pubitemid 46360389)
34. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term followup of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;40:865-873. (Pubitemid 46489550)
35. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608-612.
36. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;2:595-602.
37. Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;6:694-698. (Pubitemid 38858204)
38. Lee S, Jin Kim Y, Yong Jeon T, et al. Obesity is the only independent factor associated with ultrasound-diagnosed nonalcoholic fatty disease: a cross-sectional case-control study. Scand J Gastroenterol. 2006;51:566-572.
39. Hirsch S, Poniachick J, Avendano M, et al. Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver. Nutrition. 2005;2:137-141. (Pubitemid 40255721)
40. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol. 2005;37:5834-5839. (Pubitemid 41662835)
41. Sookoian S, Castano GO, Burgueno AL, et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis. 2010;2: 585-591.
42. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis. 2004;3:501-519. (Pubitemid 39141139)
43. Carulli L, Lonardo A, Lombardini S, Marchesini G, Loria P. Gender, fatty liver and GGT. Hepatology. 2006;44:278-279.
44. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health. 1987;8:253-287.
45. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y. Regular physical activity and coronary risk factors in Japanese men. Circulation. 1998;97:661-665. (Pubitemid 28090959)
46. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006;7:2023-2030. (Pubitemid 43816951)
47. Zelber-Sagi S, Nitzan-Kaliski D, Goldsmith R, et al. Role of leisure-time physical activity in alcoholic fatty liver disease: a population-based study. Hepatology. 2008;48:1791-1798.
48. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444. (Pubitemid 23046633)
49. Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care. 1998;21:539-545.
50. De Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756-761. (Pubitemid 29220775)
51. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and metabolic syndrome. Curr Opin Lipidol. 2005;16:421-427. (Pubitemid 41017626)
52. Hanley AJ, Williams K, Festa A, et al. Insulin resistance atherosclerosis study. Diabetes. 2004;53:2623-2632.
53. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart continues and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828. (Pubitemid 17178359)
54. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929-1934.
55. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289: 3000-3004. (Pubitemid 37430103)
56. Radu C, Grigoriscu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. 2008;17:255-260.
57. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year of observation period: the Manitoba study. Am J Cardiol. 1977;39:452-458. (Pubitemid 8055364)
58. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977. (Pubitemid 13080473)
59. Ruhl CE, Everhart JE. Determination of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79. (Pubitemid 36055340)
60. Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult-to-adult right lobe transplantation. Transplantation. 2000;69:2410-2415. (Pubitemid 30409013)
61. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population-examination of 503 consecutive fatal traffic casualties. Scand J Gastroenterol. 1977;12:593-597. (Pubitemid 8149779)
62. Lee RG. Nonalcoholic steatohepatitis a study of 49 patients. Hum Pathol. 1989;20:594-598.
63. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidity obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2000;12:49-51.
64. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. Lancet. 2000;356:1955-1964.
65. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53:1020-1023. (Pubitemid 38824162)
66. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222-1225. (Pubitemid 39425579)
67. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585-588.
68. Yang S, Zhu H, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptation to obesity-related oxidant stress. Arch Biochem Biophys. 2000;378:259-268. (Pubitemid 30397626)
69. Leclercq IA, Farrel GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-1075. (Pubitemid 30217691)
70. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol. 2002;37: 56-62. (Pubitemid 34713055)
71. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1497-1502. (Pubitemid 39193189)
72. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanism. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
73. Schulz E, Anter E, Keaney JF. Oxidative stress, antioxidants, and endothelial function. Curr Med Chem. 2004;11:1093-1104. (Pubitemid 38585055)
74. Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol. 2010;16:4243-4252.
75. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000. (Pubitemid 43112663)
76. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023-3028. (Pubitemid 34816338)
77. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25:1135-1141. (Pubitemid 41071163)
78. Pilz S, Scharnagl H, Tiran B, et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J Clin Endocrinol Metab. 2006;91:2542-2547. (Pubitemid 44024615)
79. Stefan N, Kantartzis K, Ulrich Häring H. Causes and metabolic consequences of fatty liver. Endocrine Reviews. 2008;29:939-960.
80. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22:1354-1358. (Pubitemid 41391311)
81. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372-1379. (Pubitemid 351813900)
82. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-2153. (Pubitemid 30253042)
83. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772. (Pubitemid 30213096)
84. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med. 2000;342: 836-843. (Pubitemid 30165206)
85. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation. 1997;96:4204-4210. (Pubitemid 28007445)
86. Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognosis value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol. 1998;82:715-719.
87. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-1801. (Pubitemid 44033299)
88. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-880. (Pubitemid 46028447)
89. Day CP. From fat to inflammation. Gastroenterology. 2006;130: 207-210. (Pubitemid 43049850)
90. Marra F, Svegliati Gastaldelli A, Baroni G, Tell C, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14:72-81.
91. Libby P. Inflammation in atherosclerosis. Nature. 2002;420: 868-874. (Pubitemid 36019640)
92. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359:2195-2207.
93. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46-54. (Pubitemid 38868922)
94. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004;109:2046-2049. (Pubitemid 38620209)
95. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94:e27-e31.
96. Schram K, Sweeney G. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc Med. 2008;18:199-205.
97. Perseghin G, Lattuada G, De Cobelli F, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47: 51-58. (Pubitemid 351171041)
98. Taskinen MR. Lipoprotein lipase in diabetes. Diabetes Metab Rev. 1987;3:551-570.
99. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005;31:429-439.
100. Frenais R, Nazih H, Ouguerram K, et al. In vivo evidence for the role of lipoprotein lipase activity in the regulation of Apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J Clin Endocrinol Metab. 2001;86:1962-1967. (Pubitemid 32472905)
101. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765. (Pubitemid 43357551)
102. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc. 1996; 276:875-881. (Pubitemid 26301606)
103. Kwiterovich PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002;90:30i-47i.
104. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidemia. Curr Opin Lipidol. 2006;17:238-246.
105. Cassader M, Gambino R, Musso G, et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids. 2001;36:1117-1124. (Pubitemid 33143966)
106. Roche HM, Gibney MJ. The impact of postprandial lipemia in accelerating atherothrombosis. J Cardiovasc Risk. 2000;7:317-324.
107. Tanaka A. Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb. 2004;11:322-329.
108. Brown ML, Ramprassad MP, Umeda PK, et al. A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc Natl Acad Sci USA. 2000;97:7488-7493. (Pubitemid 30431490)
109. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensivity in overweight/obese humans. J Clin Invest. 2009;119:1322-1334.
110. Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 2005;42:1175-1183. (Pubitemid 43112685)
111. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909-916. (Pubitemid 36397404)
112. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin responses to dietary fat: possible pathogenetic role in NASH. Hepatology. 2008;47:1167-1177. (Pubitemid 351547903)
113. Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol. 2002;22:173-178. (Pubitemid 34076250)
114. Fan JG, Chen LH, Xu ZJ, Zeng MD. Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver. World J Gastroenterol. 2001;7:710-712.
115. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-430. (Pubitemid 43899639)
116. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implication for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
117. Targher G. Non-alcoholic fatty liver disease and cardiovascular disease. Curr Cardio Risk Rep. 2010;4:32-39.
118. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is a an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009;58:1281-1288.
119. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121-129.
120. Assy N, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol. 2009;15:1809-1815.
121. Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. Arch Intern Med. 2008;22:2449-2458.
122. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease.World J Gastroenterol. 2010;16:2579-2588.
123. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology. 2008;47:1947-1954. (Pubitemid 351945562)
124. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18-the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009;30:1103-1109.
125. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854. (Pubitemid 46631552)
126. Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, et al. Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes. Intern Med J. 2010;40:437-442.
127. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, Chan FK, Sung JJ, Chan HL. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut. 2011;60:829-836
128. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;9285:893-894. (Pubitemid 32900577)
129. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;1:188-196. (Pubitemid 38461481)
130. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34: 738-744. (Pubitemid 32927998)
131. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;1:275-286. (Pubitemid 351160260)
132. Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol. 2007;4:242-250.
133. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006;1:233-234. (Pubitemid 41721093)
134. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;11:1643-1647. (Pubitemid 43727474)
135. Browning JD. Stains and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 2006;44:466-471. (Pubitemid 44214886)
136. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745-750. (Pubitemid 32927999)
137. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009;8:942-954.
138. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
139. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;7:679-692.
140. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
141. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472-479.
142. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.